Claris Lifesciences along with its subsidiaries (Claris) has received the Abbreviated New Drug Application (ANDA) approval for Bupivacaine Hydrochloride in 8.25% Dextrose Injection USP, 7.5 mg/mL, Single-dose Ampules with 2ml fill volumes, in the United States of America (US).
With this approval, Claris now has a total of 15 approvals and 25 under approval ANDAs, the total addressable market size of the approved ANDAs is estimated to be a little above $300 million. The company expects more product approvals during the year, which will allow it to continue its growth in the US market.
Bupivacaine Hydroxhloride in Dextorse Injection is a local or regional anesthesia used as a long-acting anesthetic during surgical procedures.
| Company Name | CMP |
|---|---|
| Redington | 216.55 |
| Adani Enterprises | 2286.65 |
| Amrapali Industries | 17.63 |
| Rashi Peripheral | 461.70 |
| PDS | 278.40 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: